Organovo Competitors

INmune Bio (NASDAQ:INMB) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.

Institutional & Insider Ownership

7.4% of INmune Bio shares are owned by institutional investors. Comparatively, 48.7% of Organovo shares are owned by institutional investors. 58.9% of INmune Bio shares are owned by insiders. Comparatively, 5.1% of Organovo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

INmune Bio has a beta of 3.01, meaning that its share price is 201% more volatile than the S&P 500. Comparatively, Organovo has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.

Profitability

This table compares INmune Bio and Organovo's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares INmune Bio and Organovo's revenue, earnings per share (EPS) and valuation.

INmune Bio has higher earnings, but lower revenue than Organovo.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for INmune Bio and Organovo, as reported by MarketBeat.com.

INmune Bio currently has a consensus price target of $19.25, suggesting a potential upside of 41.34%. Given INmune Bio's higher probable upside, equities analysts clearly believe INmune Bio is more favorable than Organovo.

Summary

INmune Bio beats Organovo on 7 of the 9 factors compared between the two stocks.

ADMA Biologics (NASDAQ:ADMA) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares ADMA Biologics and Organovo's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and price targets for ADMA Biologics and Organovo, as provided by MarketBeat.

ADMA Biologics currently has a consensus target price of $7.80, indicating a potential upside of 372.73%. Given ADMA Biologics' higher probable upside, equities analysts plainly believe ADMA Biologics is more favorable than Organovo.

Insider and Institutional Ownership

48.9% of ADMA Biologics shares are held by institutional investors. Comparatively, 48.7% of Organovo shares are held by institutional investors. 11.7% of ADMA Biologics shares are held by company insiders. Comparatively, 5.1% of Organovo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares ADMA Biologics and Organovo's revenue, earnings per share and valuation.

Organovo has lower revenue, but higher earnings than ADMA Biologics.

Risk and Volatility

ADMA Biologics has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Organovo has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

Summary

ADMA Biologics beats Organovo on 7 of the 11 factors compared between the two stocks.

LogicBio Therapeutics (NASDAQ:LOGC) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Institutional and Insider Ownership

33.8% of LogicBio Therapeutics shares are owned by institutional investors. Comparatively, 48.7% of Organovo shares are owned by institutional investors. 23.4% of LogicBio Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Organovo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares LogicBio Therapeutics and Organovo's net margins, return on equity and return on assets.

Risk & Volatility

LogicBio Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Organovo has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

Valuation & Earnings

This table compares LogicBio Therapeutics and Organovo's top-line revenue, earnings per share (EPS) and valuation.

Organovo has higher revenue and earnings than LogicBio Therapeutics.

Analyst Ratings

This is a summary of current recommendations for LogicBio Therapeutics and Organovo, as provided by MarketBeat.com.

LogicBio Therapeutics currently has a consensus target price of $18.50, indicating a potential upside of 214.63%. Given LogicBio Therapeutics' higher possible upside, analysts plainly believe LogicBio Therapeutics is more favorable than Organovo.

Summary

Organovo beats LogicBio Therapeutics on 5 of the 9 factors compared between the two stocks.

Gamida Cell (NASDAQ:GMDA) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.

Risk and Volatility

Gamida Cell has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Organovo has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.

Insider & Institutional Ownership

48.7% of Organovo shares are held by institutional investors. 5.1% of Organovo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Gamida Cell and Organovo's revenue, earnings per share and valuation.

Organovo has higher revenue and earnings than Gamida Cell.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Gamida Cell and Organovo, as provided by MarketBeat.com.

Gamida Cell presently has a consensus target price of $20.25, indicating a potential upside of 164.71%. Given Gamida Cell's higher probable upside, equities research analysts plainly believe Gamida Cell is more favorable than Organovo.

Profitability

This table compares Gamida Cell and Organovo's net margins, return on equity and return on assets.

Summary

Organovo beats Gamida Cell on 5 of the 9 factors compared between the two stocks.

Organovo (NASDAQ:ONVO) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Organovo and Genfit, as reported by MarketBeat.com.

Genfit has a consensus target price of $43.60, suggesting a potential upside of 911.60%. Given Genfit's higher probable upside, analysts plainly believe Genfit is more favorable than Organovo.

Volatility and Risk

Organovo has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Genfit has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.

Valuation & Earnings

This table compares Organovo and Genfit's revenue, earnings per share and valuation.

Organovo has higher earnings, but lower revenue than Genfit.

Profitability

This table compares Organovo and Genfit's net margins, return on equity and return on assets.

Insider & Institutional Ownership

48.7% of Organovo shares are owned by institutional investors. Comparatively, 0.4% of Genfit shares are owned by institutional investors. 5.1% of Organovo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Genfit beats Organovo on 6 of the 10 factors compared between the two stocks.

Organovo (NASDAQ:ONVO) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Volatility & Risk

Organovo has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Organovo and Protara Therapeutics, as provided by MarketBeat.

Protara Therapeutics has a consensus target price of $47.6667, suggesting a potential upside of 201.31%. Given Protara Therapeutics' higher possible upside, analysts plainly believe Protara Therapeutics is more favorable than Organovo.

Institutional and Insider Ownership

48.7% of Organovo shares are owned by institutional investors. Comparatively, 83.1% of Protara Therapeutics shares are owned by institutional investors. 5.1% of Organovo shares are owned by company insiders. Comparatively, 45.7% of Protara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Organovo and Protara Therapeutics' gross revenue, earnings per share and valuation.

Protara Therapeutics has lower revenue, but higher earnings than Organovo.

Profitability

This table compares Organovo and Protara Therapeutics' net margins, return on equity and return on assets.

Summary

Protara Therapeutics beats Organovo on 8 of the 9 factors compared between the two stocks.